Titre:oncodesign – biopharmaceutical company – oncology and non-oncology
La description :-- -- fr en jp news careers contact us menu about offerings innovation model technologies investors [press release] oncodesign presents its results for the 1st half of 2018 > sharp increase in oper...
Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations.
Notre service GeoIP a trouvé l'hôte oncodesign.fr.Actuellement, hébergé dans Italy et son fournisseur de services est IUNET BNET .
Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.
Expires:
Mon, 01 Oct 2018 03:27:47 GMT
X-Powered-By:
PHP/7.0.30
Transfer-Encoding:
chunked
Set-Cookie:
SERVERID31396=2340223; path=/; max-age=900
Content-Encoding:
gzip
Server:
Apache
Last-Modified:
Mon, 01 Oct 2018 02:27:47 GMT
Connection:
keep-alive
Pragma:
no-cache
Cache-Control:
no-cache, max-age=3600
Date:
Mon, 01 Oct 2018 02:27:47 GMT
P3P:
CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM"
MX preference = 20, mail exchanger = smtp1.oncodesign.fr.
HtmlToText
-- -- fr en jp news careers contact us menu about offerings innovation model technologies investors [press release] oncodesign presents its results for the 1st half of 2018 > sharp increase in operating revenue: up 32% at €15.0 million, driven by sales growth of 58% to €9.2 million. > higher operating expenses reflecting the more rapid development of the service business and increased r&d spending for partnership and licensing activities > cash position of €9.8 million at 30 june 2018 read the press release discover innovative new therapies against cancer and serious illnesses with unmet medical needs access our innovation platform via three offerings: as a service , under a partnership or based on a licensing arrangement discover our offerings our unique, patient-centered innovation model thanks to its precision medicine platform, oncodesign is able to orient at a very early stage its research and the development of innovative therapeutic solutions for resistant and unresponsive diseases explore our model a continuum of technologies from the molecule to the patient for over 20 years, oncodesign has invested in translational research technologies to bring valuable innovation into the initial phases of the drug discovery process. discover our technologies about oncodesign read our vision management introduce our management key figures see our figures discover our sab discover our mission oncodesign in the world find us offerings service starting out from your targets or your molecules, we design and select the best drug candidates idds (integrated drug discovery services) proof of concept - pharmacology dmpk bioanalysis biobanking translational biomarkers biodecontamination / biosafety partnership use our development programs at a very early stage by entering into a long-term strategic partnership kinase inhibitor development programs technology partnership licensing license technologies, drug candidates and radiotracers from oncodesign’s portfolio kinase inhibitors in oncology, cns and inflammation technologies therapeutic areas & experimental models our innovation model etiology knowledge: identifying is a big step towards solving puzzles discovery investigation: the quest for efficacy experimentation potential: formulate new treatments technologies nanocyclix® the power and selectivity of nanocyclix® molecules applied to the entire kinome. learn more t.o.t® streamline the choice of therapeutic orientation for your projects by qualifying in vitro the potential of your molecules and your targets. learn more predict® select the best drug candidates and their biomarkers by harnessing our pharmacological expertise. learn more chi-mice® use our humanized models to reproduce the targeted pathology effectively: pdx, in vivo humanization of tissues from human stem cells (liver, immune system, skin, stroma, etc.). learn more pharmimage® integrate our multi-modal pharmaco-imaging expertise with your preclinical and clinical projects. learn more oncosnipe® set the direction at a very early stage for the research and development of therapeutic solutions for resistant and unresponsive patients. learn more oncodesign news [press release] oncodesign: 1st half 2018 results 26/09/2018 learn more [press release] precision medicine: cap digital and medicen paris-region team up with oncodesign, servier and intersystems on hu-precimed project 18/09/2018 learn more [congress] discovery on target – 25-28 september – boston - usa interested in next generation of kinase inhibitors, integrated drug discovery partner or services using our technological platforms? learn more [congress] europdx workshop - 1-3 october 2018 - weggis - switzerland join caroline mignard at the europdx workshop for great talks and discussions on all aspects of patient-derived xenograft tumor research! learn more see all news investors financial calendar stock price documentation press releases subscribe to the investor alert investors contacts word from the chairman since our april 2014 ipo, we have accelerated our development and have become an international biopharma company specialized in precision medicine pursuing ambitious development objectives underpinned by acquisition-led growth and investments in innovative therapeutic research programs. learn more careers oncodesign’s mission is to discover innovative new therapies effective against cancer and serious illnesses with unmet medical needs. oncodesign has opted to take the time to build up all the dimensions of its organization—scientific, technical, business, starting with the most crucial one, the human dimension . our values job offers/work-study arrangements internship available spontaneous applications contact us select a service (*) sales & marketing bu finance & shareholders relationship bu press relation bu administrative bu human resources bu invalid input (*) invalid input (*) invalid input (*) please write a subject for your message. (*) please let us know your message. send sales team if you have any questions, please contact the member of our sales team responsible for your geographical region, and we will get back to you as swiftly as we can. connect with us now about oncodesign vision our mission key figures management scientific advisory board where to find us offerings services partnerships licensing therapeutic areas & experimental models our innovation model etiology discovery experimentation our technologies nanocyclix® t.o.t.® predict® chi-mice® pharmimage® oncosnipe® investors a word from the chairman financial calendar shares documentation sign up for email alerts investors contacts carreers our values job offers/work-study arrangements internships spontaneous applications news upcoming events webinars scientific publications contact contact us sales team cookies legal notice contact us (c) copyright oncodesign - all right reserved 20 rue jean mazen | b.p. 27627 | 21076 dijon cedex | france | tel.+33 (0)3.80.78.82.60 | fax +33 (0)3.80.78.82.61 newsletter- en subscribe to the general newsletter (*) invalid input (*) invalid input sign-up subscribe to the investor alert by closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them. i agree! learn more
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
%% %% This is the AFNIC Whois server. %% %% complete date format : DD/MM/YYYY %% short date format : DD/MM %% version : FRNIC-2.5 %% %% Rights restricted by copyright. %% See https://www.afnic.fr/en/products-and-services/services/whois/whois-special-notice/ %% %% Use '-h' option to obtain more information about this service. %% %% [2600:3c03:0000:0000:f03c:91ff:feae:779d REQUEST] >> oncodesign.fr %% %% RL Net [#########.] - RL IP [#######...] %%
TYPE domain RegrInfo DISCLAIMER % % This is the AFNIC Whois server. % % complete date format : DD/MM/YYYY % short date format : DD/MM % version : FRNIC-2.5 % % Rights restricted by copyright. % See https://www.afnic.fr/en/products-and-services/services/whois/whois-special-notice/ % % Use '-h' option to obtain more information about this service. % % [2600:3c03:0000:0000:f03c:91ff:feae:779d REQUEST] >> oncodesign.fr % % RL Net [#########.] - RL IP [#######...] %
REGISTERED yes
ADMIN
HANDLE GC1786-FRNIC
TYPE PERSON
CONTACT Genne Catherine
ADDRESS ONCODESIGN parc Techn Toison d'Or 28, rue de Broglie 21000 Dijon
COUNTRY FR
PHONE +33 3 80 78 82 60
FAX +33 3 80 78 82 61
EMAIL cgenne@oncodesign.fr
SPONSOR ORANGE
CHANGED 2004-09-30
ANONYMOUS NO
OBSOLETED NO
SOURCE FRNIC
TECH
HANDLE OH251-FRNIC
TYPE ROLE
CONTACT OLEANE Hostmaster
ADDRESS France Telecom 13, rue de Javel 75015 Paris
COUNTRY FR
PHONE +33 1 53 95 14 00
FAX +33 1 53 95 14 01
EMAIL domaine-admin@list.orange-ftgroup.com
ADMIN-C CP460-FRNIC
TECH-C CW13-FRNIC
NOTIFY hm-dbm-msgs@ripe.net
SPONSOR ORANGE
CHANGED 2004-10-29
ANONYMOUS NO
OBSOLETED NO
SOURCE FRNIC
OWNER
HANDLE O1789-FRNIC
TYPE ORGANIZATION
CONTACT ONCODESIGN
ADDRESS parc Techn Toison d'Or28, rue de Broglie 21000 Dijon
Nous utilisons des cookies pour personnaliser votre expérience sur notre site. En poursuivant votre navigation, vous acceptez cette utilisation. Apprendre encore plus
oncodesign.fr rapport :
Visitez le site